Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Neoplasms of the CNS

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 229 articles:
HTML format



Single Articles


    April 2021
  1. AMIN S, Baine M, Meza J, Lin C, et al
    The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type.
    BMC Cancer. 2021;21:387.
    PubMed     Abstract available


  2. RADES D, Witteler J, Olbrich D, Trillenberg P, et al
    A prospective interventional study evaluating seizure activity during a radiotherapy course for high-grade gliomas (SURF-ROGG).
    BMC Cancer. 2021;21:386.
    PubMed     Abstract available


    March 2021
  3. XI J, Hassan B, Katumba RGN, Khaddour K, et al
    The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
    BMC Cancer. 2021;21:285.
    PubMed     Abstract available


  4. ZHANG C, Liu H, Xu P, Tan Y, et al
    Identification and validation of a five-lncRNA prognostic signature related to Glioma using bioinformatics analysis.
    BMC Cancer. 2021;21:251.
    PubMed     Abstract available


  5. RYDEN I, Thurin E, Carstam L, Smits A, et al
    Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study.
    BMC Cancer. 2021;21:248.
    PubMed     Abstract available


  6. MILLS MN, Walker C, Thawani C, Naz A, et al
    Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
    BMC Cancer. 2021;21:223.
    PubMed     Abstract available


  7. MASALHA W, Daka K, Woerner J, Pompe N, et al
    Metabolic alterations in meningioma reflect the clinical course.
    BMC Cancer. 2021;21:211.
    PubMed     Abstract available


    February 2021
  8. KHAN M, Zhao Z, Arooj S, Liao G, et al
    Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis.
    BMC Cancer. 2021;21:167.
    PubMed     Abstract available


  9. KEOGH RJ, Aslam R, Hennessy MA, Coyne Z, et al
    One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
    BMC Cancer. 2021;21:140.
    PubMed     Abstract available


  10. GUAN Y, Xiong J, Pan M, Shi W, et al
    Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience.
    BMC Cancer. 2021;21:123.
    PubMed     Abstract available


    January 2021
  11. LIU G, Liu D, Huang J, Li J, et al
    Comprehensive analysis of ceRNA network related to lincRNA in glioblastoma and prediction of clinical prognosis.
    BMC Cancer. 2021;21:98.
    PubMed     Abstract available


  12. LIU FM, Gao YF, Kong Y, Guan Y, et al
    The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.
    BMC Cancer. 2021;21:83.
    PubMed     Abstract available


  13. WEN J, Chen W, Zhu Y, Zhang P, et al
    Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
    BMC Cancer. 2021;21:81.
    PubMed     Abstract available


  14. CHEN B, Chen C, Zhang Y, Xu J, et al
    Recent incidence trend of elderly patients with glioblastoma in the United States, 2000-2017.
    BMC Cancer. 2021;21:54.
    PubMed     Abstract available


  15. WANG Y, Zhang Y, Hong Y, Zeng P, et al
    Advance directives and end-of-life care: knowledge and preferences of patients with brain Tumours from Anhui, China.
    BMC Cancer. 2021;21:25.
    PubMed     Abstract available


    December 2020
  16. HIGGINS DMO, Caliva M, Schroeder M, Carlson B, et al
    Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas.
    BMC Cancer. 2020;20:1213.
    PubMed     Abstract available


    November 2020
  17. YU X, Wang Y, Yuan Z, Yu H, et al
    Benefit of dosimetry distribution for patients with multiple brain metastases from non-small cell lung cancer by a Cyberknife stereotactic radiosurgery (SRS) system.
    BMC Cancer. 2020;20:1144.
    PubMed     Abstract available


  18. LI X, Meng Y
    Analyses of metastasis-associated genes in IDH wild-type glioma.
    BMC Cancer. 2020;20:1114.
    PubMed     Abstract available


  19. ZHU Z, Lan Y, Wang L, Ge J, et al
    A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    BMC Cancer. 2020;20:1072.
    PubMed     Abstract available


    October 2020
  20. CHIA BSH, Leong JY, Ong ALK, Lim C, et al
    Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol.
    BMC Cancer. 2020;20:1045.
    PubMed     Abstract available


  21. DING X, Yang L, Geng X, Zou Y, et al
    CircRNAs as potential biomarkers for the clinicopathology and prognosis of glioma patients: a meta-analysis.
    BMC Cancer. 2020;20:1005.
    PubMed     Abstract available


  22. GUENOLE M, Lucia F, Bourbonne V, Dissaux G, et al
    Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases.
    BMC Cancer. 2020;20:991.
    PubMed     Abstract available


  23. FENG J, Ouyang Y, Xu D, He Q, et al
    Genetic variants in MIR17HG affect the susceptibility and prognosis of glioma in a Chinese Han population.
    BMC Cancer. 2020;20:976.
    PubMed     Abstract available


  24. BLECKMANN A, Kirchner B, Nietert M, Peeck M, et al
    Impact of pre-OP independence in patients with limited brain metastases on long-term survival.
    BMC Cancer. 2020;20:973.
    PubMed     Abstract available


    September 2020
  25. WANG J, Tong L, Lin G, Wang H, et al
    Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients.
    BMC Cancer. 2020;20:931.
    PubMed     Abstract available


  26. VUONG HG, Nguyen TQ, Ngo TNM, Nguyen HC, et al
    The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis.
    BMC Cancer. 2020;20:897.
    PubMed     Abstract available


  27. WANG J, Liu Z, Pang Q, Zhang T, et al
    Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.
    BMC Cancer. 2020;20:837.
    PubMed     Abstract available


    August 2020
  28. BEN-ZION BERLINER M, Katz LH, Derazne E, Levine H, et al
    Height as a risk factor in meningioma: a study of 2 million Israeli adolescents.
    BMC Cancer. 2020;20:786.
    PubMed     Abstract available


  29. FRANCESCHI E, Minichillo S, Mura A, Tosoni A, et al
    Adjuvant chemotherapy in average-risk adult medulloblastoma patients improves survival: a long term study.
    BMC Cancer. 2020;20:755.
    PubMed     Abstract available


  30. WANG C, Liu S, Peng L, Zhang K, et al
    Correction to: Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas.
    BMC Cancer. 2020;20:736.
    PubMed     Abstract available


    July 2020
  31. SHEN CC, Cheng WY, Lee CH, Dai XJ, et al
    Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment.
    BMC Cancer. 2020;20:709.
    PubMed     Abstract available


  32. HEUSER VD, Kiviniemi A, Lehtinen L, Munthe S, et al
    Multiple formin proteins participate in glioblastoma migration.
    BMC Cancer. 2020;20:710.
    PubMed     Abstract available


  33. LOCSEI Z, Farkas R, Borbasne Farkas K, Sebestyen K, et al
    Assessment of the results and hematological side effects of 3D conformal and IMRT/ARC therapies delivered during craniospinal irradiation of childhood tumors with a follow-up period of five years.
    BMC Cancer. 2020;20:702.
    PubMed     Abstract available


  34. OUYANG W, Yu J, Zhou Y, Hu J, et al
    Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer.
    BMC Cancer. 2020;20:699.
    PubMed     Abstract available


  35. ZHAO Y, He JY, Cui JZ, Meng ZQ, et al
    Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing.
    BMC Cancer. 2020;20:690.
    PubMed     Abstract available


  36. ZHANG F, Liu R, Zhang H, Liu C, et al
    Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells.
    BMC Cancer. 2020;20:673.
    PubMed     Abstract available


  37. GAN C, Pierscianek D, El Hindy N, Ahmadipour Y, et al
    The predominant expression of cancer stem cell marker ALDH1A3 in tumor infiltrative area is associated with shorter overall survival of human glioblastoma.
    BMC Cancer. 2020;20:672.
    PubMed     Abstract available


  38. LIN J, Yu L, Fu Y, Chen H, et al
    A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report.
    BMC Cancer. 2020;20:630.
    PubMed     Abstract available


  39. MEZEI T, Hajdu M, Czigleczki G, Lotz G, et al
    Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review.
    BMC Cancer. 2020;20:615.
    PubMed     Abstract available


    June 2020
  40. MEHTA P, Janssen S, Fahlbusch FB, Schmid SM, et al
    Sparing the hippocampus and the hypothalamic- pituitary region during whole brain radiotherapy: a volumetric modulated arc therapy planning study.
    BMC Cancer. 2020;20:610.
    PubMed     Abstract available


  41. XU T, Zhang X, Zhang S, Liu C, et al
    Imaging features and prognostic value of (18)F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study.
    BMC Cancer. 2020;20:596.
    PubMed     Abstract available


  42. WANG C, Liu S, Peng L, Zhang K, et al
    Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas.
    BMC Cancer. 2020;20:591.
    PubMed     Abstract available


  43. DING L, Zhang F, He Q, Li Z, et al
    Differentiation of suprasellar meningiomas from non-functioning pituitary macroadenomas by (18)F-FDG and (13)N-Ammonia PET/CT.
    BMC Cancer. 2020;20:564.
    PubMed     Abstract available


  44. LOW SYY, Bte Syed Sulaiman N, Tan EEK, Ng LP, et al
    Cerebrospinal fluid cytokines in metastatic group 3 and 4 medulloblastoma.
    BMC Cancer. 2020;20:554.
    PubMed     Abstract available


  45. CAI Z, Yang S, Li X, Chen F, et al
    Viral infection and glioma: a meta-analysis of prognosis.
    BMC Cancer. 2020;20:549.
    PubMed     Abstract available


  46. GROSU AL, Frings L, Bentsalo I, Oehlke O, et al
    Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) - a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG).
    BMC Cancer. 2020;20:532.
    PubMed     Abstract available


  47. BARCISZEWSKA AM
    Total DNA methylation as a biomarker of DNA damage and tumor malignancy in intracranial meningiomas.
    BMC Cancer. 2020;20:509.
    PubMed     Abstract available


  48. HOWELL AE, Robinson JW, Wootton RE, McAleenan A, et al
    Testing for causality between systematically identified risk factors and glioma: a Mendelian randomization study.
    BMC Cancer. 2020;20:508.
    PubMed     Abstract available


  49. DEVECKA M, Duma MN, Wilkens JJ, Kampfer S, et al
    Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting.
    BMC Cancer. 2020;20:501.
    PubMed     Abstract available


    May 2020
  50. BUCKSCH K, Zachariae S, Aretz S, Buttner R, et al
    Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study.
    BMC Cancer. 2020;20:460.
    PubMed     Abstract available


  51. CORELL A, Ferreyra Vega S, Hoefling N, Carstam L, et al
    The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    BMC Cancer. 2020;20:450.
    PubMed     Abstract available


  52. WHITMIRE P, Rickertsen CR, Hawkins-Daarud A, Carrasco E Jr, et al
    Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients.
    BMC Cancer. 2020;20:447.
    PubMed     Abstract available


  53. KIESEL B, Thome CM, Weiss T, Jakola AS, et al
    Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee.
    BMC Cancer. 2020;20:410.
    PubMed     Abstract available


  54. WAKUDA K, Yamaguchi H, Kenmotsu H, Fukuda M, et al
    A phase II study of Osimertinib for patients with radiotherapy-naive CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
    BMC Cancer. 2020;20:370.
    PubMed     Abstract available


    April 2020
  55. MITSUYA K, Nakasu Y, Hayashi N, Deguchi S, et al
    Retrospective analysis of salvage surgery for local progression of brain metastasis previously treated with stereotactic irradiation: diagnostic contribution, functional outcome, and prognostic factors.
    BMC Cancer. 2020;20:331.
    PubMed     Abstract available


  56. TAMURA R, Morimoto Y, Kosugi K, Sato M, et al
    Correction to: Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
    BMC Cancer. 2020;20:301.
    PubMed     Abstract available


  57. SHAH N, Liu Z, Tallman RM, Mohammad A, et al
    Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis.
    BMC Cancer. 2020;20:292.
    PubMed     Abstract available


  58. FARIA GM, Soares IDP, D'Alincourt Salazar M, Amorim MR, et al
    Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism.
    BMC Cancer. 2020;20:294.
    PubMed     Abstract available


  59. FURUSE M, Kuwabara H, Ikeda N, Hattori Y, et al
    PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
    BMC Cancer. 2020;20:277.
    PubMed     Abstract available


    March 2020
  60. LU C, Liu J, Yao M, Li L, et al
    Downregulation of S100 calcium binding protein A12 inhibits the growth of glioma cells.
    BMC Cancer. 2020;20:261.
    PubMed     Abstract available


  61. NAWROCKI S, Sugajska A
    Study protocol: watchful observation of patients with limited small cell lung cancer instead of the PCI-prospective, multi-center one-arm study.
    BMC Cancer. 2020;20:231.
    PubMed     Abstract available


  62. WANG L, Ge J, Lan Y, Shi Y, et al
    Tumor mutational burden is associated with poor outcomes in diffuse glioma.
    BMC Cancer. 2020;20:213.
    PubMed     Abstract available


  63. BROWN NF, Ng SM, Brooks C, Coutts T, et al
    A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.
    BMC Cancer. 2020;20:198.
    PubMed     Abstract available


  64. TAMURA R, Morimoto Y, Kosugi K, Sato M, et al
    Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
    BMC Cancer. 2020;20:196.
    PubMed     Abstract available


    February 2020
  65. LESUEUR P, Kao W, Leconte A, Geffrelot J, et al
    Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial.
    BMC Cancer. 2020;20:147.
    PubMed     Abstract available


  66. CHO I, Lee H, Yoon SE, Ryu KJ, et al
    Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
    BMC Cancer. 2020;20:120.
    PubMed     Abstract available


  67. PATRIKIDOU A, Chaigneau L, Isambert N, Kitikidou K, et al
    Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA).
    BMC Cancer. 2020;20:117.
    PubMed     Abstract available


  68. TREUTWEIN M, Steger F, Loeschel R, Koelbl O, et al
    The influence of radiotherapy techniques on the plan quality and on the risk of secondary tumors in patients with pituitary adenoma.
    BMC Cancer. 2020;20:88.
    PubMed     Abstract available


    January 2020
  69. ANG SYL, Lee L, See AAQ, Ang TY, et al
    Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
    BMC Cancer. 2020;20:79.
    PubMed     Abstract available


  70. LIU K, Jiang G, Zhang A, Li Z, et al
    Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
    BMC Cancer. 2020;20:76.
    PubMed     Abstract available


  71. NAKANO T, Aoyama H, Saito H, Tanabe S, et al
    The neurocognitive function change criteria after whole-brain radiation therapy for brain metastasis, in reference to health-related quality of life changes: a prospective observation study.
    BMC Cancer. 2020;20:66.
    PubMed     Abstract available


  72. SRIVASTAVA C, Irshad K, Gupta Y, Sarkar C, et al
    NFsmall ka, CyrillicB is a critical transcriptional regulator of atypical cadherin FAT1 in glioma.
    BMC Cancer. 2020;20:62.
    PubMed     Abstract available


  73. UMPHLETT M, Shea S, Tome-Garcia J, Zhang Y, et al
    Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
    BMC Cancer. 2020;20:47.
    PubMed     Abstract available


  74. LIANG J, Lv X, Lu C, Ye X, et al
    Prognostic factors of patients with Gliomas - an analysis on 335 patients with Glioblastoma and other forms of Gliomas.
    BMC Cancer. 2020;20:35.
    PubMed     Abstract available


  75. GE JJ, Li C, Qi SP, Xue FJ, et al
    Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study.
    BMC Cancer. 2020;20:24.
    PubMed     Abstract available


  76. ENRIQUEZ PEREZ J, Kopecky J, Visse E, Darabi A, et al
    Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
    BMC Cancer. 2020;20:7.
    PubMed     Abstract available


    December 2019
  77. PERREAULT S, Larouche V, Tabori U, Hawkin C, et al
    A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
    BMC Cancer. 2019;19:1250.
    PubMed     Abstract available


  78. SUN C, Dai X, Zhao D, Wang H, et al
    Mesenchymal stem cells promote glioma neovascularization in vivo by fusing with cancer stem cells.
    BMC Cancer. 2019;19:1240.
    PubMed     Abstract available


  79. GANGEMI V, Mignogna C, Guzzi G, Lavano A, et al
    Impact of [(64)Cu][Cu(ATSM)] PET/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report.
    BMC Cancer. 2019;19:1197.
    PubMed     Abstract available


  80. DA COSTA AABA, Dos Santos ES, Cotrim DP, Pandolfi NC, et al
    Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis.
    BMC Cancer. 2019;19:1194.
    PubMed     Abstract available


  81. HAO Z, Guo D
    EGFR mutation: novel prognostic factor associated with immune infiltration in lower-grade glioma; an exploratory study.
    BMC Cancer. 2019;19:1184.
    PubMed     Abstract available


    November 2019
  82. ZHONG QY, Fan EX, Feng GY, Chen QY, et al
    A gene expression-based study on immune cell subtypes and glioma prognosis.
    BMC Cancer. 2019;19:1116.
    PubMed     Abstract available


  83. LI Z, Shen D, Zhang J, Zhang J, et al
    Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis.
    BMC Cancer. 2019;19:1104.
    PubMed     Abstract available


  84. YU W, Ren X, Hu C, Tan Y, et al
    Glioma SOX2 expression decreased after adjuvant therapy.
    BMC Cancer. 2019;19:1087.
    PubMed     Abstract available


  85. SALVUCCI M, Zakaria Z, Carberry S, Tivnan A, et al
    System-based approaches as prognostic tools for glioblastoma.
    BMC Cancer. 2019;19:1092.
    PubMed     Abstract available


  86. CHATURVEDI NK, Mahapatra S, Kesherwani V, Kling MJ, et al
    Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
    BMC Cancer. 2019;19:1056.
    PubMed     Abstract available


  87. BAZAN F, Dobi E, Royer B, Curtit E, et al
    Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer.
    BMC Cancer. 2019;19:1029.
    PubMed     Abstract available


    October 2019
  88. CHEN YH, Chen YF, Chen CY, Shih JY, et al
    Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    BMC Cancer. 2019;19:1006.
    PubMed     Abstract available


  89. STOPPEK AK, Kebir S, Junker A, Keyvani K, et al
    Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report.
    BMC Cancer. 2019;19:995.
    PubMed     Abstract available


  90. BRITO C, Azevedo A, Esteves S, Marques AR, et al
    Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    BMC Cancer. 2019;19:968.
    PubMed     Abstract available


    September 2019
  91. JANIK K, Treda C, Wlodarczyk A, Peciak J, et al
    A way to understand idiopathic senescence and apoptosis in primary glioblastoma cells - possible approaches to circumvent these phenomena.
    BMC Cancer. 2019;19:923.
    PubMed     Abstract available


  92. JIANG Q, Xie Q, Hu C, Yang Z, et al
    Glioma malignancy is linked to interdependent and inverse AMOG and L1 adhesion molecule expression.
    BMC Cancer. 2019;19:911.
    PubMed     Abstract available


  93. TAKASHIMA Y, Yoshimura T, Kano Y, Hayano A, et al
    Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells.
    BMC Cancer. 2019;19:910.
    PubMed     Abstract available


    August 2019
  94. GOMEZ-ACEVEDO H, Patterson JD, Sardar S, Gokden M, et al
    SMARC-B1 deficient sinonasal carcinoma metastasis to the brain with next generation sequencing data: a case report of perineural invasion progressing to leptomeningeal invasion.
    BMC Cancer. 2019;19:827.
    PubMed     Abstract available


  95. LI X, Meng Y
    Survival analysis of immune-related lncRNA in low-grade glioma.
    BMC Cancer. 2019;19:813.
    PubMed     Abstract available


  96. CHEN Y, Wei J, Cai J, Liu A, et al
    Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
    BMC Cancer. 2019;19:793.
    PubMed     Abstract available


  97. XIAO J, Jin Y, Nie J, Chen F, et al
    Diagnostic and grading accuracy of (18)F-FDOPA PET and PET/CT in patients with gliomas: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:767.
    PubMed     Abstract available


  98. CHEN JC, Lee IN, Huang C, Wu YP, et al
    Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
    BMC Cancer. 2019;19:756.
    PubMed     Abstract available


    July 2019
  99. IMAIZUMI J, Shida D, Narita Y, Miyakita Y, et al
    Prognostic factors of brain metastases from colorectal cancer.
    BMC Cancer. 2019;19:755.
    PubMed     Abstract available


  100. XI S, Sai K, Hu W, Wang F, et al
    Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China.
    BMC Cancer. 2019;19:717.
    PubMed     Abstract available


  101. YE T, Wei L, Shi J, Jiang K, et al
    Sirtuin1 activator SRT2183 suppresses glioma cell growth involving activation of endoplasmic reticulum stress pathway.
    BMC Cancer. 2019;19:706.
    PubMed     Abstract available


  102. LIU J, Jin B, Su H, Qu X, et al
    Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    BMC Cancer. 2019;19:702.
    PubMed     Abstract available


    June 2019
  103. SKAGA E, Kulesskiy E, Fayzullin A, Sandberg CJ, et al
    Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naive glioblastoma.
    BMC Cancer. 2019;19:628.
    PubMed     Abstract available


  104. PARK AK, Lee JY, Cheong H, Ramaswamy V, et al
    Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
    BMC Cancer. 2019;19:571.
    PubMed     Abstract available


  105. BUSTAMANTE EDUARDO M, Popovici V, Imboden S, Aebi S, et al
    Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
    BMC Cancer. 2019;19:549.
    PubMed     Abstract available


  106. ZAKRZEWSKA M, Gruszka R, Stawiski K, Fendler W, et al
    Expression-based decision tree model reveals distinct microRNA expression pattern in pediatric neuronal and mixed neuronal-glial tumors.
    BMC Cancer. 2019;19:544.
    PubMed     Abstract available


    May 2019
  107. VAN BUSSEL MTJ, Beijnen JH, Brandsma D
    Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.
    BMC Cancer. 2019;19:519.
    PubMed     Abstract available


  108. LIU CC, Yu CF, Wang SC, Li HY, et al
    Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor.
    BMC Cancer. 2019;19:473.
    PubMed     Abstract available


  109. ZHONG C, Shu M, Ye J, Wang X, et al
    Oncogenic Ras is downregulated by ARHI and induces autophagy by Ras/AKT/mTOR pathway in glioblastoma.
    BMC Cancer. 2019;19:441.
    PubMed     Abstract available


  110. CUNCANNON M, Wong M, Jayamanne D, Guo L, et al
    Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma.
    BMC Cancer. 2019;19:445.
    PubMed     Abstract available


  111. DU N, Bao W, Zhang K, Lu X, et al
    Cytogenetic characterization of the malignant primitive neuroectodermal SK-PN-DW tumor cell line.
    BMC Cancer. 2019;19:412.
    PubMed     Abstract available


    April 2019
  112. KRUG S, Teupe F, Michl P, Gress TM, et al
    Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome.
    BMC Cancer. 2019;19:362.
    PubMed     Abstract available


  113. HE Q, Zhang L, Zhang B, Shi X, et al
    Diagnostic accuracy of (13)N-ammonia PET, (11)C-methionine PET and (18)F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma.
    BMC Cancer. 2019;19:332.
    PubMed     Abstract available


  114. SAVCI-HEIJINK CD, Halfwerk H, Koster J, Horlings HM, et al
    A specific gene expression signature for visceral organ metastasis in breast cancer.
    BMC Cancer. 2019;19:333.
    PubMed     Abstract available


  115. KOPER-LENKIEWICZ OM, Kaminska J, Milewska A, Sawicki K, et al
    Serum and cerebrospinal fluid Neudesin concentration and Neudesin Quotient as potential circulating biomarkers of a primary brain tumor.
    BMC Cancer. 2019;19:319.
    PubMed     Abstract available


  116. COWMAN S, Fan YN, Pizer B, See V, et al
    Decrease of Nibrin expression in chronic hypoxia is associated with hypoxia-induced chemoresistance in some brain tumour cells.
    BMC Cancer. 2019;19:300.
    PubMed     Abstract available


  117. DJUZENOVA CS, Fiedler V, Memmel S, Katzer A, et al
    Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells.
    BMC Cancer. 2019;19:299.
    PubMed     Abstract available


    March 2019
  118. SCHORB E, Finke J, Ihorst G, Kasenda B, et al
    Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
    BMC Cancer. 2019;19:287.
    PubMed     Abstract available


  119. HUA C, Zhao G, Li Y, Bie L, et al
    Correction to: Minichromosome Maintenance (MCM) family as potential diagnostic and prognostic tumor markers for human gliomas.
    BMC Cancer. 2019;19:260.
    PubMed     Abstract available


  120. SUN L, Jin X, Xie L, Xu G, et al
    Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression.
    BMC Cancer. 2019;19:247.
    PubMed     Abstract available


  121. LESUEUR P, Lequesne J, Grellard JM, Dugue A, et al
    Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
    BMC Cancer. 2019;19:198.
    PubMed     Abstract available


  122. KAZLAUSKAS A, Darinskas A, Meskys R, Tamasauskas A, et al
    Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
    BMC Cancer. 2019;19:197.
    PubMed     Abstract available


  123. HICKMANN AK, Frick M, Hadaschik D, Battke F, et al
    Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
    BMC Cancer. 2019;19:192.
    PubMed     Abstract available


  124. HUMMEL S, Kohlmann W, Kollmeyer TM, Jenkins R, et al
    The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database.
    BMC Cancer. 2019;19:190.
    PubMed     Abstract available


    February 2019
  125. LOW SYY, Kuick CH, Seow WY, Bte Syed Sulaiman N, et al
    Primary paediatric epidural sarcomas: molecular exploration of three cases.
    BMC Cancer. 2019;19:182.
    PubMed     Abstract available


  126. LAPRIE A, Ken S, Filleron T, Lubrano V, et al
    Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
    BMC Cancer. 2019;19:167.
    PubMed     Abstract available


  127. OSTROVSKAYA A, Hick C, Hutchinson DS, Stringer BW, et al
    Expression and activity of the calcitonin receptor family in a sample of primary human high-grade gliomas.
    BMC Cancer. 2019;19:157.
    PubMed     Abstract available


  128. LI WY, Zhao TT, Xu HM, Wang ZN, et al
    The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:145.
    PubMed     Abstract available


  129. GE M, Zhan Q, Zhang Z, Ji X, et al
    Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases.
    BMC Cancer. 2019;19:143.
    PubMed     Abstract available


  130. STILLER CA, Bayne AM, Chakrabarty A, Kenny T, et al
    Incidence of childhood CNS tumours in Britain and variation in rates by definition of malignant behaviour: population-based study.
    BMC Cancer. 2019;19:139.
    PubMed     Abstract available


  131. WANG J, Chen J
    Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
    BMC Cancer. 2019;19:131.
    PubMed     Abstract available


  132. KIM TM, Ko YH, Ha SJ, Lee HH, et al
    Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers.
    BMC Cancer. 2019;19:119.
    PubMed     Abstract available


  133. HEYNCKES S, Daka K, Franco P, Gaebelein A, et al
    Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
    BMC Cancer. 2019;19:117.
    PubMed     Abstract available


    January 2019
  134. DARLIX A, Hirtz C, Thezenas S, Maceski A, et al
    The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
    BMC Cancer. 2019;19:110.
    PubMed     Abstract available


  135. ZUO MR, Liang RF, Li M, Xiang YF, et al
    A comprehensive study of risk factors for post-operative pneumonia following resection of meningioma.
    BMC Cancer. 2019;19:100.
    PubMed     Abstract available


  136. GOLDSMITH CS, Kim SM, Karunarathna N, Neuendorff N, et al
    Correction to: inhibition of p38 MAPK activity leads to cell type-specific effects on the molecular circadian clock and time-dependent reduction of glioma cell invasiveness.
    BMC Cancer. 2019;19:101.
    PubMed     Abstract available


  137. YIN X, Yan D, Qiu M, Huang L, et al
    Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:95.
    PubMed     Abstract available


  138. LI Z, Mbah NE, Overmeyer JH, Sarver JG, et al
    The JNK signaling pathway plays a key role in methuosis (non-apoptotic cell death) induced by MOMIPP in glioblastoma.
    BMC Cancer. 2019;19:77.
    PubMed     Abstract available


  139. KIM R, Keam B, Kim S, Kim M, et al
    Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    BMC Cancer. 2019;19:19.
    PubMed     Abstract available


    December 2018
  140. TAN WL, Ng QS, Lim C, Tan EH, et al
    Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
    BMC Cancer. 2018;18:1288.
    PubMed     Abstract available


  141. FRAZAO L, do Carmo Martins M, Nunes VM, Pimentel J, et al
    BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas.
    BMC Cancer. 2018;18:1259.
    PubMed     Abstract available


  142. MOHAMMAD AS, Adkins CE, Shah N, Aljammal R, et al
    Permeability changes and effect of chemotherapy in brain adjacent to tumor in an experimental model of metastatic brain tumor from breast cancer.
    BMC Cancer. 2018;18:1225.
    PubMed     Abstract available


  143. MONNIER A, Boniface R, Bouvet R, Etcheverry A, et al
    The expression of EMX2 lead to cell cycle arrest in glioblastoma cell line.
    BMC Cancer. 2018;18:1213.
    PubMed     Abstract available


  144. LI L, Huang Y, Gao Y, Shi T, et al
    EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.
    BMC Cancer. 2018;18:1215.
    PubMed     Abstract available


  145. TAN WL, Ng QS, Lim C, Tan EH, et al
    Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
    BMC Cancer. 2018;18:1198.
    PubMed     Abstract available


    November 2018
  146. HWANG K, Lee KS, Choe G, Cho BG, et al
    Secondary glioblastoma after treatment of intracranial germinoma - would radiation-only therapy still be safe? Case report.
    BMC Cancer. 2018;18:1119.
    PubMed     Abstract available


    October 2018
  147. TUNG B, Ma D, Wang S, Oyinlade O, et al
    Kruppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
    BMC Cancer. 2018;18:1025.
    PubMed     Abstract available


  148. AIKO N, Shimokawa T, Miyazaki K, Misumi Y, et al
    Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    BMC Cancer. 2018;18:1012.
    PubMed     Abstract available


  149. DA SILVA BB, Eulalio Filho WMN, Costa PVL, Silva RA, et al
    A rare case of primary breast angiosarcoma in a male: a case report.
    BMC Cancer. 2018;18:978.
    PubMed     Abstract available


  150. LORIGUET L, Morisse MC, Dremaux J, Collet L, et al
    Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma.
    BMC Cancer. 2018;18:964.
    PubMed     Abstract available


  151. FOLYOVICH A, Varga V, Varallyay G, Kozak L, et al
    A case report of isolated distal upper extremity weakness due to cerebral metastasis involving the hand knob area.
    BMC Cancer. 2018;18:947.
    PubMed     Abstract available


    September 2018
  152. STRAUBE C, Kessel KA, Schmidt-Graf F, Krieg SM, et al
    A trend towards a more intense adjuvant treatment of low-grade-gliomas in tertiary centers in Germany after RTOG 9802 - results from a multi-center survey.
    BMC Cancer. 2018;18:907.
    PubMed     Abstract available


  153. SONG X, Shu XH, Wu ML, Zheng X, et al
    Postoperative resveratrol administration improves prognosis of rat orthotopic glioblastomas.
    BMC Cancer. 2018;18:871.
    PubMed     Abstract available


  154. MIKKELSEN VE, Stensjoen AL, Granli US, Berntsen EM, et al
    Angiogenesis and radiological tumor growth in patients with glioblastoma.
    BMC Cancer. 2018;18:862.
    PubMed     Abstract available


    August 2018
  155. URUGA H, Moriguchi S, Takahashi Y, Ogawa K, et al
    Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
    BMC Cancer. 2018;18:825.
    PubMed     Abstract available


    July 2018
  156. DU D, Yuan J, Ma W, Ning J, et al
    Clinical significance of FBXO17 gene expression in high-grade glioma.
    BMC Cancer. 2018;18:773.
    PubMed     Abstract available


  157. KIM T, Choi HY, Lee HS, Jung SH, et al
    Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL).
    BMC Cancer. 2018;18:729.
    PubMed     Abstract available


  158. ZHONG C, Chen Y, Tao B, Peng L, et al
    LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway.
    BMC Cancer. 2018;18:722.
    PubMed     Abstract available


    June 2018
  159. VALKONEN M, Haapasalo H, Rilla K, Tyynela-Korhonen K, et al
    Elevated expression of hyaluronan synthase 2 associates with decreased survival in diffusely infiltrating astrocytomas.
    BMC Cancer. 2018;18:664.
    PubMed     Abstract available


  160. POUCHIEU C, Gruber A, Berteaud E, Menegon P, et al
    Increasing incidence of central nervous system (CNS) tumors (2000-2012): findings from a population based registry in Gironde (France).
    BMC Cancer. 2018;18:653.
    PubMed     Abstract available


    May 2018
  161. WANG Y, Guan G, Cheng W, Jiang Y, et al
    ARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL.
    BMC Cancer. 2018;18:599.
    PubMed     Abstract available


  162. KARJALAINEN SL, Haapasalo HK, Aspatwar A, Barker H, et al
    Carbonic anhydrase related protein expression in astrocytomas and oligodendroglial tumors.
    BMC Cancer. 2018;18:584.
    PubMed     Abstract available


  163. MARTINI M, de Pascalis I, D'Alessandris QG, Fiorentino V, et al
    VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
    BMC Cancer. 2018;18:553.
    PubMed     Abstract available


  164. GUIDA M, Tommasi S, Strippoli S, Natalicchio MI, et al
    The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
    BMC Cancer. 2018;18:552.
    PubMed     Abstract available


  165. MCDONALD MA, Sanghvi P, Bykowski J, Daniels GA, et al
    Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
    BMC Cancer. 2018;18:549.
    PubMed     Abstract available


  166. PEYSER A, Bristow SL, Hershlag A
    Two successful pregnancies following fertility preservation in a patient with anaplastic astrocytoma: a case report.
    BMC Cancer. 2018;18:544.
    PubMed     Abstract available


  167. LEE C, Lee J, Choi SA, Kim SK, et al
    M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas.
    BMC Cancer. 2018;18:535.
    PubMed     Abstract available


  168. SCHULZE M, Hutterer M, Sabo A, Hoja S, et al
    Chronophin regulates active vitamin B6 levels and transcriptomic features of glioblastoma cell lines cultured under non-adherent, serum-free conditions.
    BMC Cancer. 2018;18:524.
    PubMed     Abstract available


  169. HEGGE B, Sjottem E, Mikkola I
    Generation of a PAX6 knockout glioblastoma cell line with changes in cell cycle distribution and sensitivity to oxidative stress.
    BMC Cancer. 2018;18:496.
    PubMed     Abstract available


    April 2018
  170. VOSOUGHI E, Lee JM, Miller JR, Nosrati M, et al
    Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.
    BMC Cancer. 2018;18:490.
    PubMed     Abstract available


  171. JIN J, Gao Y, Zhang J, Wang L, et al
    Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer.
    BMC Cancer. 2018;18:446.
    PubMed     Abstract available


  172. LAUBER C, Klink B, Seifert M
    Comparative analysis of histologically classified oligodendrogliomas reveals characteristic molecular differences between subgroups.
    BMC Cancer. 2018;18:399.
    PubMed     Abstract available


  173. CHIO CC, Chen KY, Chang CK, Chuang JY, et al
    Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells.
    BMC Cancer. 2018;18:379.
    PubMed     Abstract available


  174. BOTTCHER MA, Held-Feindt J, Synowitz M, Lucius R, et al
    Modeling treatment-dependent glioma growth including a dormant tumor cell subpopulation.
    BMC Cancer. 2018;18:376.
    PubMed     Abstract available


  175. FATAI AA, Gamieldien J
    A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer.
    BMC Cancer. 2018;18:377.
    PubMed     Abstract available


    March 2018
  176. HUA G, Yanjiao H, Qian L, Jichao W, et al
    Detection of circulating tumor cells in patients with pituitary tumors.
    BMC Cancer. 2018;18:336.
    PubMed     Abstract available


  177. AABERG-JESSEN C, Sorensen MD, Matos ALSA, Moreira JM, et al
    Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas.
    BMC Cancer. 2018;18:270.
    PubMed     Abstract available


  178. RANJAN S, Quezado M, Garren N, Boris L, et al
    Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases.
    BMC Cancer. 2018;18:239.
    PubMed     Abstract available


    February 2018
  179. HAN Y, Yan LF, Wang XB, Sun YZ, et al
    Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
    BMC Cancer. 2018;18:215.
    PubMed     Abstract available


  180. SCHIMMEL WCM, Verhaak E, Hanssens PEJ, Gehring K, et al
    A randomised trial to compare cognitive outcome after gamma knife radiosurgery versus whole brain radiation therapy in patients with multiple brain metastases: research protocol CAR-study B.
    BMC Cancer. 2018;18:218.
    PubMed     Abstract available


  181. JIAO XD, Ding C, Zang YS, Yu G, et al
    Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report.
    BMC Cancer. 2018;18:206.
    PubMed     Abstract available


  182. TOTON E, Romaniuk A, Konieczna N, Hofmann J, et al
    Impact of PKCepsilon downregulation on autophagy in glioblastoma cells.
    BMC Cancer. 2018;18:185.
    PubMed     Abstract available


  183. MARITAZ C, Lemare F, Laplanche A, Demirdjian S, et al
    High-dose thiotepa-related neurotoxicity and the role of tramadol in children.
    BMC Cancer. 2018;18:177.
    PubMed     Abstract available


  184. AHN MJ, Lee K, Lee KH, Kim JW, et al
    Combination of anti-PD-1 therapy and stereotactic radiosurgery for a gastric cancer patient with brain metastasis: a case report.
    BMC Cancer. 2018;18:173.
    PubMed     Abstract available


  185. MOREN L, Perryman R, Crook T, Langer JK, et al
    Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.
    BMC Cancer. 2018;18:167.
    PubMed     Abstract available


  186. VASAIKAR S, Tsipras G, Landazuri N, Costa H, et al
    Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?
    BMC Cancer. 2018;18:154.
    PubMed     Abstract available


  187. LIU F, Huang J, Zhang L, Fan F, et al
    Screening for distress in patients with primary brain tumor using distress thermometer: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:124.
    PubMed     Abstract available


    January 2018
  188. EISEMANN T, Costa B, Strelau J, Mittelbronn M, et al
    An advanced glioma cell invasion assay based on organotypic brain slice cultures.
    BMC Cancer. 2018;18:103.
    PubMed     Abstract available


  189. CHOU SY, Yen SL, Huang CC, Huang EY, et al
    Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy.
    BMC Cancer. 2018;18:105.
    PubMed     Abstract available


  190. RICCIARDI GRR, Russo A, Franchina T, Schifano S, et al
    Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
    BMC Cancer. 2018;18:97.
    PubMed     Abstract available


  191. GOLDSMITH CS, Kim SM, Karunarathna N, Neuendorff N, et al
    Inhibition of p38 MAPK activity leads to cell type-specific effects on the molecular circadian clock and time-dependent reduction of glioma cell invasiveness.
    BMC Cancer. 2018;18:43.
    PubMed     Abstract available


  192. XIA L, Fang C, Chen G, Sun C, et al
    Relationship between the extent of resection and the survival of patients with low-grade gliomas: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:48.
    PubMed     Abstract available


  193. STRAUBE C, Scherb H, Gempt J, Kirschke J, et al
    Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma - the GlioCave study (NOA 17 - ARO 2016/3 - DKTK ROG trial).
    BMC Cancer. 2018;18:15.
    PubMed     Abstract available


    December 2017
  194. CHANG CH, Liu WT, Hung HC, Gean CY, et al
    Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells.
    BMC Cancer. 2017;17:905.
    PubMed     Abstract available


  195. CONDE M, Michen S, Wiedemuth R, Klink B, et al
    Chromosomal instability induced by increased BIRC5/Survivin levels affects tumorigenicity of glioma cells.
    BMC Cancer. 2017;17:889.
    PubMed     Abstract available


    November 2017
  196. YOMO S, Oguchi K
    Prospective study of 11C-methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment.
    BMC Cancer. 2017;17:713.
    PubMed     Abstract available


    October 2017
  197. TRAN LT, Lai HTM, Koriyama C, Uwatoko F, et al
    The association between high birth weight and the risks of childhood CNS tumors and leukemia: an analysis of a US case-control study in an epidemiological database.
    BMC Cancer. 2017;17:687.
    PubMed     Abstract available


    August 2017
  198. NOH MG, Oh SJ, Ahn EJ, Kim YJ, et al
    Prognostic significance of E-cadherin and N-cadherin expression in Gliomas.
    BMC Cancer. 2017;17:583.
    PubMed     Abstract available


    July 2017
  199. ZINDLER JD, Bruynzeel AME, Eekers DBP, Hurkmans CW, et al
    Whole brain radiotherapy versus stereotactic radiosurgery for 4-10 brain metastases: a phase III randomised multicentre trial.
    BMC Cancer. 2017;17:500.
    PubMed     Abstract available


  200. MIELE E, Po A, Begalli F, Antonucci L, et al
    beta-arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells.
    BMC Cancer. 2017;17:488.
    PubMed     Abstract available


    June 2017
  201. WIBROE M, Cappelen J, Castor C, Clausen N, et al
    Cerebellar mutism syndrome in children with brain tumours of the posterior fossa.
    BMC Cancer. 2017;17:439.
    PubMed     Abstract available


  202. HAYASHI N, Takahashi H, Hasegawa Y, Higuchi F, et al
    A nationwide multi-institutional retrospective study to identify prognostic factors and develop a graded prognostic assessment system for patients with brain metastases from uterine corpus and cervical cancer.
    BMC Cancer. 2017;17:397.
    PubMed     Abstract available


    May 2017
  203. TEYSSONNEAU D, Daste A, Dousset V, Hoepffner JL, et al
    Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.
    BMC Cancer. 2017;17:323.
    PubMed     Abstract available


    April 2017
  204. URUP T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, et al
    Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients.
    BMC Cancer. 2017;17:278.
    PubMed     Abstract available


  205. TRUBICKA J, Zemojtel T, Hecht J, Falana K, et al
    The germline variants in DNA repair genes in pediatric medulloblastoma: a challenge for current therapeutic strategies.
    BMC Cancer. 2017;17:239.
    PubMed     Abstract available


  206. LI MX, He H, Ruan ZH, Zhu YX, et al
    Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
    BMC Cancer. 2017;17:245.
    PubMed     Abstract available


    March 2017
  207. DALAN AB, Gulluoglu S, Tuysuz EC, Kuskucu A, et al
    Simultaneous analysis of miRNA-mRNA in human meningiomas by integrating transcriptome: A relationship between PTX3 and miR-29c.
    BMC Cancer. 2017;17:207.
    PubMed     Abstract available


  208. NARAYAN RS, Fedrigo CA, Brands E, Dik R, et al
    The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
    BMC Cancer. 2017;17:204.
    PubMed     Abstract available


  209. JENSEN SS, Petterson SA, Halle B, Aaberg-Jessen C, et al
    Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo.
    BMC Cancer. 2017;17:178.
    PubMed     Abstract available


    February 2017
  210. PANOSYAN EH, Lin HJ, Koster J, Lasky JL 3rd, et al
    In search of druggable targets for GBM amino acid metabolism.
    BMC Cancer. 2017;17:162.
    PubMed     Abstract available


  211. DEWAN R, Pemov A, Dutra AS, Pak ED, et al
    First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    BMC Cancer. 2017;17:127.
    PubMed     Abstract available


  212. LI Y, Li J, Woo YM, Shen Z, et al
    Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model.
    BMC Cancer. 2017;17:126.
    PubMed     Abstract available


  213. SHANNON S, Jia D, Entersz I, Beelen P, et al
    Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901.
    BMC Cancer. 2017;17:121.
    PubMed     Abstract available


  214. GERSEY ZC, Rodriguez GA, Barbarite E, Sanchez A, et al
    Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species.
    BMC Cancer. 2017;17:99.
    PubMed     Abstract available


    January 2017
  215. DENG X, Zheng Z, Lin B, Su H, et al
    The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
    BMC Cancer. 2017;17:42.
    PubMed     Abstract available


  216. RADES D, Janssen S, Dziggel L, Blanck O, et al
    A matched-pair study comparing whole-brain irradiation alone to radiosurgery or fractionated stereotactic radiotherapy alone in patients irradiated for up to three brain metastases.
    BMC Cancer. 2017;17:30.
    PubMed     Abstract available


  217. FROMBERG A, Rabe M, Oppermann H, Gaunitz F, et al
    Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells.
    BMC Cancer. 2017;17:3.
    PubMed     Abstract available


    December 2016
  218. YOMO S, Hayashi M
    Is upfront stereotactic radiosurgery a rational treatment option for very elderly patients with brain metastases? A retrospective analysis of 106 consecutive patients age 80 years and older.
    BMC Cancer. 2016;16:948.
    PubMed     Abstract available


    November 2016
  219. WONG ET, Timmons J, Callahan A, O'Loughlin L, et al
    Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.
    BMC Cancer. 2016;16:914.
    PubMed     Abstract available


  220. MUROTA Y, Tabu K, Taga T
    Requirement of ABC transporter inhibition and Hoechst 33342 dye deprivation for the assessment of side population-defined C6 glioma stem cell metabolism using fluorescent probes.
    BMC Cancer. 2016;16:847.
    PubMed     Abstract available


    October 2016
  221. OEHLKE O, Mix M, Graf E, Schimek-Jasch T, et al
    Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).
    BMC Cancer. 2016;16:769.
    PubMed     Abstract available


    April 2016
  222. GRAMATZKI D, Roth P, Felsberg J, Hofer S, et al
    Chemotherapy for intracranial ependymoma in adults.
    BMC Cancer. 2016;16:287.
    PubMed     Abstract available


    January 2016
  223. AKIMOTO J, Fukuhara H, Suda T, Nagai K, et al
    Clinicopathological analysis in patients with neuroendocrine tumors that metastasized to the brain.
    BMC Cancer. 2016;16:36.
    PubMed     Abstract available


  224. CHOI SA, Kwak PA, Kim SK, Park SH, et al
    In vivo bioluminescence imaging for leptomeningeal dissemination of medulloblastoma in mouse models.
    BMC Cancer. 2016;16:723.
    PubMed     Abstract available


  225. SCHORB E, Finke J, Ferreri AJ, Ihorst G, et al
    High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma-a randomized phase III trial (MATRix).
    BMC Cancer. 2016;16:282.
    PubMed     Abstract available


  226. NIIBE Y, Nishimura T, Inoue T, Karasawa K, et al
    Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
    BMC Cancer. 2016;16:659.
    PubMed     Abstract available


  227. FLECKENSTEIN J, Petroff A, Schafers HJ, Wehler T, et al
    Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    BMC Cancer. 2016;16:348.
    PubMed     Abstract available


  228. KIM S, Nam SJ, Kwon D, Kim H, et al
    MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
    BMC Cancer. 2016;16:363.
    PubMed     Abstract available


  229. ANGELINO G, De Pasquale MD, De Sio L, Serra A, et al
    NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications.
    BMC Cancer. 2016;16:512.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: